<DOC>
	<DOCNO>NCT02207361</DOCNO>
	<brief_summary>Paclitaxel plus Epirubicin metastatic breast cancer recommend scheme National Comprehensive Cancer Network ( NCCN ) guideline . Paclitaxel Combination Carboplatin also effective Metastatic Breast Cancer ( MBC ) clinical study small sample .</brief_summary>
	<brief_title>Paclitaxel Combination With Carboplatin Versus Paclitaxel Plus Epirubicin Metastatic Breast Cancer</brief_title>
	<detailed_description>A Randomized Prospective Clinical Trial Paclitaxel Combination Carboplatin Versus Paclitaxel plus Epirubicin First-Line Treatment Metastatic Breast Cancer . The primary endpoint study progression free survival ( PFS ) . The secondary endpoint overall response rate ( ORR ) , overall survival ( OS ) safety .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>female ≥ 18 year old , ECOG 02 KPS≥60 , Expected lifetime 12 week . Pregnancy , Paclitaxel , platinum anthracyclinebased drug ' allergy , Severe Infection .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>